We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 5

1.
Figure 3

Figure 3. From: Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine; impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.

Plasma Viral RNA load in individual macaques. Immunizations are described in Table 1 and materials and methods. Monkeys were challenged intravenously 4 weeks after the final immunization with 80 TCID-50 SHIV-E. Each line represents the viral loads of individual monkeys.

Josephine H. Cox, et al. Vaccine. ;30(10):1830-1840.
2.
Figure 1

Figure 1. From: Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine; impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.

Serum antibody binding to subtype E gp140 was assessed prior to immunization and at multiple time points after the priming and boosting immunizations. The data is presented as the mean titer of the 5 monkeys in each of the groups. Immunizations are described in Table 1 and the materials and methods. Arrows indicate immunizations.

Josephine H. Cox, et al. Vaccine. ;30(10):1830-1840.
3.
Figure 4

Figure 4. From: Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine; impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.

Plasma Viral RNA load averages by immunization group. Immunizations are described in Table 1 and materials and methods. Monkeys were challenged intravenously 4 weeks after the final immunization with 80 TCID-50 SHIV-E. * p<0.02 at weeks 1, 2, 3 and 4 between rDNA/rMVA gp140 and controls

Josephine H. Cox, et al. Vaccine. ;30(10):1830-1840.
4.
Figure 5

Figure 5. From: Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine; impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.

Mean CD4 cell counts after challenge. Monkeys were challenged intravenously 4 weeks after the final immunization with 80 TCID-50 SHIV-E, levels of CD4 and CD8 were measured using flow based assays. The % CD4 are shown in figure 5A and CD/CD8 ratios in figure 5B. Significant stabilization of CD4 T cells and CD4/CD8 ratios were obtained at weeks 3, 4, 6 and 8 weeks post-challenge (p < 0.05 shown by *).

Josephine H. Cox, et al. Vaccine. ;30(10):1830-1840.
5.
Figure 2

Figure 2. From: Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine; impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.

IFN-γELISPOT. PBMC from all macaques were collected at baseline, 2 weeks post the second, third and forth immunizations (weeks 0, 6, 14, and 26), on the day of challenge, 2 weeks pre and post challenge (weeks 28, 30 and 32) and 2 years after challenge. PBMC were stimulated with either pools of 5 SIV Gag 10-mer Mamu-A*01 binding peptides (Figure 2A) or pools of SIV Gag 20-mer peptides representing the whole of Gag (Figure 2B). The bars represent the mean SFC/106 PBMC +/− the standard error of the mean for 2-3 Mamu-A*01 macaques in figure 2A and 5-6 macaques in group 2B. For each group, the bars from left to right are for each of the indicated time points with the clear and hashed bars representing pre and post challenge responses respectively. The vaccines are indicated in the boxes on the x-axis and are detailed in Table 1, the macaques in the control groups 6 and 7 were combined.

Josephine H. Cox, et al. Vaccine. ;30(10):1830-1840.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk